Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab

Leukemia and Lymphoma

Volumn 46, Issue 11, 2005, Pages 1645-1649

  Woehrer, Stefan ^a   Streubel, Berthold ^a   Chott, Andreas ^a   Hoffmann, Martha ^a   Raderer, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

MALT lymphoma; Plasmacytic differentiation

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE F 18; RITUXIMAB;

ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER LOCALIZATION; CASE REPORT; CELL DIFFERENTIATION; CELL TRANSFORMATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG TUMOR; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PANCYTOPENIA; PLASMA CELL; PLASMACYTOMA; PRIORITY JOURNAL; SIDE EFFECT; STOMACH LYMPHOMA;

AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CELL DIFFERENTIATION; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MALE; PLASMA CELLS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 28244447342     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500178399     Document Type: Article

References (23)

1. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983;52:1410-1416.
2. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000;13: 193-207.
3. Pileri SA, Milani M, Fraternali-Orcioni G, Sabattini E. From the R.E.A.L. Classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities? Ann Oncol 1998;9:607-612.
4. Isaacson PG. Gastric MALT lymphoma: from concept to cure. Ann Oncol 1999;10:637-645.
5. Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997;89:1350-1355.
6. Isaacson P, Müller-Hermelink HK, Piris MA, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Jaffe ES, Harris NL, Sha VJ, editors. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp 157-160.
7. Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol 2002;2:323-335.
8. Ben-Ayed F, Halphen M, Najjar T, et al. Treatment of alpha chain disease. Results of a prospective study in 21 Tunisian patients by the Tunisian-French intestinal Lymphoma Study Group. Cancer 1989;63:1251-1256.
9. Price SK. Immunoproliferative small intestinal disease: a study of 13 cases with alpha heavy-chain disease. Histopathology 1990;17:7-17.
10. Raderer M, Jager G, Brugger S, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 2003;65:306-310.
11. Datta YH, Kampalath B, Binion DG. Rituximab-induced remission of a gastric MALT lymphoma. Leuk Lymphoma 2004;45:1297-1299.
12. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979-1983.
13. Nuckel H, Meller D, Steuhl KP, Duhrsen U. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. Eur J Haematol 2004;73:258-262.
14. Ling NR, MacLennan IC, Mason DY. B-cell and plasma cell antigens: new and previously definded clusters. In: McMichael AJ, Beverly PCL, Cobbold S, editors. Leukocyte typing III: white cell differentiation antigens. Oxford: Oxford University Press; 1987. p. 302.
15. Raderer M, Vorbeck F, Formanek M, et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer 2000; 83:454-457.
16. Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999;10:1185-1189.
17. Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995;13:2524-2529.
18. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-2745.
19. Hoffmann M, Kletter K, Becherer A, Jager U, Chott A, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003;64:336-340.
20. Finelli A, Pagano G, Amato B, D'Armiento F, Iaffaioli RV, Persico G. [Solitary gastric plasmacytoma. Case report and review of the literature]. Minerva Chir 1994;49:991-994.
21. Gonzalez Cueto D, Bruno S, Bustos Fernandez LM, Narbaitz M. [Gastric solitary plasmacytoma associated with + Helicobacter pylori infection]. Acta Gastroenterol Latinoam 1999;29:119-123.
22. Hamilton JW, McCluggage WG, Jones F, Collins J. Extra-medullary gastric plasmacytoma. Ulster Med J 1999;68: 103-105.
23. Wohrer S, Isaacson PG, Raderer M. Complete regression of primary gastric plasmacytoma following Helicobacter pylori eradication. Ann Hematol 2004;83:666.